SCHEMBL1830976

SCHEMBL1830976

COc1ccc(Nc2cc(OC3CCN(C(=O)O)CC3)ncn2)cn1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 3/20 0.45
NAMPT P43490 8/20 0.44
EGFR P00533 4/20 0.43
BTK Q06187 3/20 0.43
ITK Q08881 1/20 0.42
FLT3 P36888 3/20 0.42
CDK2 P24941 1/20 0.42
CDK6 Q00534 1/20 0.42
PIK3CD O00329 1/20 0.41
PIK3CA P42336 1/20 0.41
PIK3CB P42338 1/20 0.41
PIK3CG P48736 1/20 0.41
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41
PABPC1 P11940 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL391248 0.88 GPR119 (0.53) GPR119PIK3CD
SCHEMBL389671 0.88 GPR119 (0.60) GPR119NAMPT
SCHEMBL1070555 0.87 GPR119 (0.47) GPR119NAMPTEGFRFLT3CDK2
SCHEMBL5046848 0.84 GPR119 (0.44) GPR119FLT3CDK2CDK6PIK3CD
SCHEMBL4723183 0.82 GPR119 (0.46) GPR119NAMPTEGFRBTKITK
SCHEMBL4720714 0.82 GPR119 (0.40) GPR119NAMPTEGFRBTKITK
SCHEMBL391312 0.79 GPR119 (0.59) GPR119
SCHEMBL27734723 0.79 FGFR3 (0.41) EGFRBTKITKFLT3PIK3CD
SCHEMBL5264014 0.79 GPR119 (0.46) GPR119EGFRFLT3CDK2CDK6
SCHEMBL28781405 0.78 GPR119 (0.57) GPR119NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2322150-A2 Method of identifying GLP-1 secretagogues Arena Pharmaceuticals, Inc. (US) 2011-05-18 EP disclosed
EP-2322152-A1 Method of preparing a composition comprising a GPR119 agonist Arena Pharmaceuticals, Inc. (US) 2011-05-18 EP disclosed
EP-2322157-A1 Composition for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level Arena Pharmaceuticals, Inc. (US) 2011-05-18 EP disclosed
EP-2322151-A2 Sustained release formulation comprising a GPR119 agonist and a DPP-IV inhibitor Arena Pharmaceuticals, Inc. (US) 2011-05-18 EP disclosed
EP-2322156-A1 Composition for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level Arena Pharmaceuticals, Inc. (US) 2011-05-18 EP disclosed
EP-2116235-A1 Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level Arena Pharmaceuticals, Inc. (US) 2009-11-11 EP disclosed
EP-1808168-B1 Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level ARENA PHARM INC (US) 2009-06-03 EP disclosed
EP-1758565-B1 Method of identifying GLP-1 secretagogues ARENA PHARM INC (US) 2009-05-13 EP disclosed
EP-1997484-A2 Method of identifying GLP-1 secretagogues Arena Pharmaceuticals, Inc. (US) 2008-12-03 EP disclosed
EP-1808168-A1 Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level Arena Pharmaceuticals, Inc. (US) 2007-07-18 EP disclosed